InhaleRx Limited (AU:IRX) has released an update.
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
InhaleRx Limited is advancing its clinical trials for two inhaled drugs aimed at treating breakthrough cancer pain and panic disorder, with significant funding secured from Clendon Biotech Capital. The discontinuation of fentanyl-based medications offers an opportunity for IRX-211 to capture market share as a safer alternative in pain management. The company aims to align its market valuation with the potential success of its drugs as they progress through clinical stages.
For further insights into AU:IRX stock, check out TipRanks’ Stock Analysis page.